Merck & Company Inc (MRK)vsNeurogene Inc (NGNE)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
NGNE
Neurogene Inc
$26.49
-3.60%
HEALTHCARE · Cap: $418.59M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
NGNE
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for NGNE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NGNE
The strongest argument for NGNE centers on Debt/Equity, Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NGNE
The primary concerns for NGNE are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NGNE carries more volatility with a beta of 2.04 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Neurogene Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?